Positive News SentimentPositive NewsNASDAQ:DCTH Delcath Systems (DCTH) Stock Price, News & Analysis $13.20 +0.29 (+2.25%) Closing price 04:00 PM EasternExtended Trading$13.20 0.00 (-0.04%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Delcath Systems Stock (NASDAQ:DCTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Delcath Systems alerts:Sign Up Key Stats Today's Range$12.78▼$13.2350-Day Range$10.21▼$13.2052-Week Range$8.12▼$13.44Volume337,853 shsAverage Volume588,417 shsMarket Capitalization$455.69 millionP/E Ratio1,320.00Dividend YieldN/APrice Target$22.50Consensus RatingHold Company Overview Delcath Systems, Inc. is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma. Delcath’s approach aims to improve tumor response rates and extend progression-free survival for patients with limited treatment options. The Hepatic CHEMOSAT® Delivery System comprises specialized catheters, an extracorporeal filtration system and an isolation balloon that together isolate the liver’s vasculature, deliver high-dose chemotherapy and filter the returned blood before it reenters the patient’s systemic circulation. Delcath has achieved CE Mark approval in Europe for the treatment of unresectable liver tumors and is advancing its clinical development program in the United States, where it has completed pivotal trials assessing safety and efficacy in patients with ocular melanoma metastases in the liver. The company also continues to explore expanded indications and next-generation applications of its chemosaturation platform. Headquartered in New York, Delcath Systems operates in key oncology markets across North America and Europe, collaborating with leading cancer centers and interventional radiology departments. The organization is guided by a management team and board of directors with experience in medical device commercialization, oncology drug development and regulatory affairs. Delcath remains committed to advancing targeted regional therapies that address unmet needs in the treatment of liver tumors and improving patient outcomes through innovation and rigorous clinical investigation.AI Generated. May Contain Errors. Read More Delcath Systems Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreDCTH MarketRank™: Delcath Systems scored higher than 47% of companies evaluated by MarketBeat, and ranked 556th out of 855 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingDelcath Systems has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialDelcath Systems has a consensus price target of $22.50, representing about 70.5% upside from its current price of $13.20.Amount of Analyst CoverageDelcath Systems has only been the subject of 2 research reports in the past 90 days.Read more about Delcath Systems' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Delcath Systems are expected to decrease in the coming year, from ($0.88) to ($1.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Delcath Systems is 1,320.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 40.53.Price to Earnings Ratio vs. SectorThe P/E ratio of Delcath Systems is 1,320.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.73.Price to Book Value per Share RatioDelcath Systems has a P/B Ratio of 4.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Delcath Systems' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.84% of the float of Delcath Systems has been sold short.Short Interest Ratio / Days to CoverDelcath Systems has a short interest ratio ("days to cover") of 5.28.Change versus previous monthShort interest in Delcath Systems has recently increased by 5.99%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDelcath Systems does not currently pay a dividend.Dividend GrowthDelcath Systems does not have a long track record of dividend growth. News and Social Media3.7 / 5News SentimentN/A News SentimentDelcath Systems has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.Search InterestOnly 2 people have searched for DCTH on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows3 people have added Delcath Systems to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Delcath Systems insiders have not sold or bought any company stock.Percentage Held by Insiders19.36% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.12% of the stock of Delcath Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Delcath Systems' insider trading history. Receive DCTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DCTH Stock News HeadlinesDelcath Shareholders Approve Expanded Equity Plan and GovernanceMay 25, 2026 | theglobeandmail.comIs Delcath Systems Inc (DCTH) a Bargain After 3.8% Drop? GF Value Says UndervaluedMay 23, 2026 | gurufocus.comSolar is dead. Here’s what replaces it.Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-carbon energy source retains full government backing for eight more years - and it runs around the clock without batteries. Investment in this sector has surged 100x in seven years. The Pentagon named it a top energy priority, California mandated it, and Google, Meta, and Berkshire Hathaway are already under contract. One company controls the entire chain from the ground to the grid.July 2 at 1:00 AM | Behind the Markets (Ad)Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 15, 2026 | businesswire.comDelcath Systems Balances Growth with Rising CostsMay 8, 2026 | tipranks.comDelcath (DCTH) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comDelcath outlines at least $100M 2026 revenue as it targets 37 active centers by year-endMay 8, 2026 | msn.comDelcath Systems, Inc. (DCTH) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comSee More Headlines DCTH Stock Analysis - Frequently Asked Questions How have DCTH shares performed this year? Delcath Systems' stock was trading at $10.10 at the beginning of 2026. Since then, DCTH shares have increased by 30.7% and is now trading at $13.20. How were Delcath Systems' earnings last quarter? Delcath Systems, Inc. (NASDAQ:DCTH) posted its quarterly earnings results on Thursday, May, 7th. The company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.07. The company had revenue of $24.99 million for the quarter, compared to the consensus estimate of $23.51 million. Delcath Systems had a net margin of 0.62% and a trailing twelve-month return on equity of 0.51%. Read the conference call transcript. When did Delcath Systems' stock split? Delcath Systems shares reverse split on the morning of Tuesday, October 22nd 2019.The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How will Delcath Systems' stock buyback program work? Delcath Systems' Board of Directors approved a share repurchase program on Thursday, November 20th 2025, which authorizes the company to buy back $25,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 8.6% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board believes its shares are undervalued. How do I buy shares of Delcath Systems? Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Delcath Systems own? Based on aggregate information from My MarketBeat watchlists, some other companies that Delcath Systems investors own include Predictive Oncology (POAI), Ford Motor (F), JPMorgan Chase & Co. (JPM), Zomedica (ZOM), Wells Fargo & Company (WFC), Wayfair (W) and Bank of America (BAC). Company Calendar Last Earnings5/07/2026Today7/02/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6d) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 6 days, DCTH's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:DCTH CIK872912 Webdelcath.com Phone212-489-2100Fax212-489-2102Employees60Year Founded1988Price Target and Rating Average Price Target for Delcath Systems$22.50 High Price Target$30.00 Low Price Target$18.00 Potential Upside/Downside+70.5%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$0.01 Trailing P/E Ratio1,320.00 Forward P/E RatioN/A P/E GrowthN/ANet Income$2.70 million Net Margins0.62% Pretax Margin1.48% Return on Equity0.51% Return on Assets0.46% Debt Debt-to-Equity RatioN/A Current Ratio11.24 Quick Ratio10.33 Sales & Book Value Annual Sales$90.44 million Price / Sales5.04 Cash Flow$0.05 per share Price / Cash Flow246.97 Book Value$3.15 per share Price / Book4.19Miscellaneous Outstanding Shares34,522,000Free Float27,839,000Market Cap$455.69 million OptionableOptionable Beta0.49 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:DCTH) was last updated on 7/2/2026 by MarketBeat.com Staff. From Our PartnersPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredForget SpaceX, this is Elon’s Next BreakthroughJeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...Brownstone Research | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredA drilling crew just broke a record nobody expectedA drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Delcath Systems With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
